Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context and Transition to Focused Inquiry

The legacy context of general health and science information has long provided a foundational framework for understanding broad public health concerns, including the dissemination of knowledge about medication safety and adverse effects. Within this heritage, discussions of bone health and therapeutic interventions have been standard, with Fosamax (alendronate) emerging as a widely prescribed bisphosphonate for osteoporosis management. As public awareness evolved, so did the scope of inquiry, gradually shifting from general health education toward more specific clinical scrutiny. This transition naturally leads to a focused examination of Fosamax exposure and its potential association with osteonecrosis of the jaw (ONJ), a condition that has garnered attention in both medical literature and legal contexts. The pivot from a broad informational stance to a targeted occupational exposure concern reflects a growing need to assess risk factors in populations with prolonged or high-dose bisphosphonate use, particularly in dental and surgical settings. By moving from general health principles to a precise clinical evidence review, the discourse now centers on evaluating causation without delving into mechanistic claims, thereby maintaining a neutral academic tone while addressing the practical implications for patient care and professional practice.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with pain, swelling, and infection. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The diagnosis is primarily clinical, based on the presence of exposed bone in the oral cavity that persists for more than eight weeks in the absence of prior radiation therapy. Imaging studies, such as panoramic radiographs or CT scans, may reveal sequestra, periosteal reaction, or lytic changes. Multiscale characterization of jawbone tissue has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique microarchitecture and remodeling dynamics of the jawbone, which may predispose it to ONJ under bisphosphonate therapy.

Fosamax Pharmacology and Reported Adverse Effects

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but a serious adverse effect—osteonecrosis of the jaw (ONJ)—has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Fosamax is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. The drug's long half-life in bone—due to its strong affinity for hydroxyapatite—results in prolonged suppression of bone remodeling. This pharmacological action is central to its therapeutic efficacy but also underlies its adverse effects. Beyond ONJ, Fosamax labeling includes warnings about severe musculoskeletal pain, esophageal irritation, and atypical femur fractures. The time to onset of ONJ symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that early symptoms may not be specific to ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate, indicating a drug-specific effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The pathogenesis of bisphosphonate-related ONJ is multifactorial. Fosamax's potent inhibition of osteoclast activity reduces bone turnover, which can impair the normal healing response after dental procedures or microtrauma. The jawbone, with its high remodeling rate and constant exposure to oral microbiota, is particularly vulnerable. The multiscale characterization of jawbone tissue has revealed that its unique structural and cellular composition may contribute to a heightened sensitivity to bisphosphonate-induced remodeling suppression (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone, and can alter immune function, predisposing to infection. The presence of local infection or inflammation, often from periodontal disease or ill-fitting dentures, further exacerbates the risk. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Risk Anchors: Adequacy of Warnings and Causation Considerations

The prescribing information for Fosamax includes a specific warning under Section 5.4: 'Osteonecrosis of the Jaw' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing. The labeling also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the adequacy of these warnings has been questioned, particularly regarding the timing of onset and the need for proactive dental evaluation before initiating therapy. The labeling notes that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that early recognition and drug cessation can mitigate harm, but the variability in onset complicates risk communication. For affected patients, causation considerations involve assessing the temporal relationship between Fosamax exposure and ONJ development, the presence of other risk factors, and the exclusion of alternative causes (e.g., radiation therapy, metastatic disease). The timeline between exposure and documented harm can range from days to months, and the risk increases with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients with pre-existing dental disease or those undergoing invasive dental procedures are at higher risk. The recurrence of symptoms upon rechallenge with bisphosphonates provides strong evidence of a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinicians should weigh the benefits of Fosamax for fracture prevention against the risk of ONJ, particularly in patients with additional risk factors. The labeling recommends considering drug discontinuation after 3 to 5 years of use for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may also reduce ONJ risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with pain, swelling, and infection. Diagnosis is primarily clinical, based on the presence of exposed bone in the oral cavity persisting for more than eight weeks in the absence of prior radiation therapy. Imaging studies may reveal sequestra or lytic changes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures. The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How strong is the evidence linking Fosamax to ONJ?

The prescribing information includes a specific warning about ONJ, and clinical evidence shows a temporal relationship between Fosamax exposure and ONJ development. Recurrence of symptoms upon rechallenge with bisphosphonates provides strong evidence of a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ is rare, and the benefits of Fosamax for fracture prevention must be weighed against the risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.